Science

Development, Testing, Parameterization, and Calibration of a Human Physiologically Based Pharmacokinetic Model for the Plasticizer, Hexamoll^® Diisononyl-Cyclohexane-1, 2-Dicarboxylate Using In Silico, In Vitro, and Human Biomonitoring Data

Introduction

A physiologically based pharmacokinetic model for Hexamoll^® diisononyl-cyclohexane-1, 2-dicarboxylate was developed to interpret the biokinetics in humans after single oral doses. The model was parameterized with in vitro and in silico derived parameters and uncertainty and sensitivity analysis was used during the model development process to assess structure, biological plausibility and behavior prior to simulation and analysis of human biological monitoring data…

READ THE FULL STUDY HERE

Authors

Kevin McNally, Craig Sams, George Loizou

Exposure and Health Consequences, Health and Safety Executive, Buxton, United Kingdom

Publication

Submitted to Predictive Toxicology, a section of the journal Frontiers in Pharmacology
Received 2019 May 17; Accepted 2019 Oct 31.